$CRSP
CRISPR Therapeutics AG

2020 Q2 Form 10-Q Financial Statement

#000156459020033602 Filed on July 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $44.00K $318.0K
YoY Change -86.16% -70.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $21.40M $15.80M
YoY Change 35.44% 24.41%
% of Gross Profit
Research & Development $59.38M $39.53M
YoY Change 50.2% 54.23%
% of Gross Profit
Depreciation & Amortization $2.200M $1.000M
YoY Change 120.0% 11.11%
% of Gross Profit
Operating Expenses $80.73M $55.30M
YoY Change 45.99% 44.11%
Operating Profit -$80.69M -$54.98M
YoY Change 46.75% 47.46%
Interest Expense $0.00 -$1.000M
YoY Change -100.0% -16.67%
% of Operating Profit
Other Income/Expense, Net $1.412M $1.369M
YoY Change 3.14% 584.5%
Pretax Income -$79.28M -$53.61M
YoY Change 47.87% 40.04%
Income Tax $400.0K $100.0K
% Of Pretax Income
Net Earnings -$79.66M -$53.70M
YoY Change 48.34% 39.91%
Net Earnings / Revenue -181036.36% -16886.48%
Basic Earnings Per Share -$1.30 -$1.01
Diluted Earnings Per Share -$1.30 -$1.01
COMMON SHARES
Basic Shares Outstanding 61.42M 53.19M
Diluted Shares Outstanding 61.42M 53.19M

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $945.1M $427.9M
YoY Change 120.87% 33.84%
Cash & Equivalents $945.1M $427.9M
Short-Term Investments
Other Short-Term Assets $20.50M $10.30M
YoY Change 99.03% 4.04%
Inventory
Prepaid Expenses
Receivables $0.00 $321.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $965.6M $438.5M
YoY Change 120.22% 32.67%
LONG-TERM ASSETS
Property, Plant & Equipment $34.44M $20.16M
YoY Change 70.89% 9.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.000M $669.0K
YoY Change 946.34% -82.85%
Total Long-Term Assets $80.90M $55.77M
YoY Change 45.05% 146.78%
TOTAL ASSETS
Total Short-Term Assets $965.6M $438.5M
Total Long-Term Assets $80.90M $55.77M
Total Assets $1.047B $494.2M
YoY Change 111.74% 39.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.20M $7.143M
YoY Change 84.8% 58.73%
Accrued Expenses $36.69M $18.63M
YoY Change 96.93% 46.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.50M $31.41M
YoY Change 137.17% 69.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $61.40M $220.0K
YoY Change 27809.09% -99.68%
Total Long-Term Liabilities $61.40M $220.0K
YoY Change 27809.09% -99.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.50M $31.41M
Total Long-Term Liabilities $61.40M $220.0K
Total Liabilities $135.9M $126.6M
YoY Change 7.38% 43.82%
SHAREHOLDERS EQUITY
Retained Earnings -$393.7M
YoY Change
Common Stock $761.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $57.00K
YoY Change
Treasury Stock Shares $257.0K
Shareholders Equity $910.7M $367.7M
YoY Change
Total Liabilities & Shareholders Equity $1.047B $494.2M
YoY Change 111.74% 39.97%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$79.66M -$53.70M
YoY Change 48.34% 39.91%
Depreciation, Depletion And Amortization $2.200M $1.000M
YoY Change 120.0% 11.11%
Cash From Operating Activities -$29.27M -$36.38M
YoY Change -19.54% 44.31%
INVESTING ACTIVITIES
Capital Expenditures -$3.610M -$2.170M
YoY Change 66.36% 317.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.610M -$2.170M
YoY Change 66.36% 317.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 89.51M 29.65M
YoY Change 201.89% 694.91%
NET CHANGE
Cash From Operating Activities -29.27M -36.38M
Cash From Investing Activities -3.610M -2.170M
Cash From Financing Activities 89.51M 29.65M
Net Change In Cash 56.63M -8.900M
YoY Change -736.29% -59.55%
FREE CASH FLOW
Cash From Operating Activities -$29.27M -$36.38M
Capital Expenditures -$3.610M -$2.170M
Free Cash Flow -$25.66M -$34.21M
YoY Change -24.99% 38.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
80733000
CY2019Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2381000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5644000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3506000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1369000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5644000
us-gaap Net Income Loss
NetIncomeLoss
-102107000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59380000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21353000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-80689000
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1012000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2037000
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1412000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1412000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79277000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53614000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
379000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.94
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
379810000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1399000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13216000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-849000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-50000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-111000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61134214
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52643649
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
392195000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23472000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
15000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1832000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10696000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28114000
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
16000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1254000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12198000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-53699000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
367683000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
939425000
CY2020Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
889000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-25000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-69731000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
886097000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
82189000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6345000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15697000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-79656000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
910670000
us-gaap Profit Loss
ProfitLoss
-149387000
us-gaap Profit Loss
ProfitLoss
-102107000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2010000
us-gaap Other Noncash Expense
OtherNoncashExpense
889000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-66000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
233000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23595000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81454000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6596000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3271000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6596000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3271000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83021000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52294000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7616000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3086000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
90637000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55380000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-28000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2559000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28012000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
459812000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
951371000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
431800000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2585000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
702000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
1009000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
477000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
945068000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
427885000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6303000
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3915000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. <span style="color:#212529;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50746000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43376000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16302000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12046000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34444000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31330000
CY2020Q2 us-gaap Depreciation
Depreciation
2200000
us-gaap Depreciation
Depreciation
4300000
CY2019Q2 us-gaap Depreciation
Depreciation
1000000.0
us-gaap Depreciation
Depreciation
2000000.0
CY2020Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6784000
CY2020Q2 crsp Prepaid Expenses And Other Current Assets Fair Value Disclosure
PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure
2565000
CY2020Q2 us-gaap Property Plant And Equipment Fair Value Disclosure
PropertyPlantAndEquipmentFairValueDisclosure
9340000
CY2020Q2 crsp Operating Lease Assets Fair Value Disclosure
OperatingLeaseAssetsFairValueDisclosure
11003000
CY2020Q2 crsp Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
1226000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30180000
crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
36500000
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-36500000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10128000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15229000
CY2020Q2 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
19723000
CY2019Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
9434000
CY2020Q2 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
300000
CY2019Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
750000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1742000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2040000
CY2020Q2 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
2553000
CY2019Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
2311000
CY2020Q2 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
576000
CY2019Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
407000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1663000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36685000
CY2020Q2 crsp Accrued Expenses And Other Current Liabilities Fair Value Disclosure
AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure
3915000
CY2020Q2 crsp Operating Lease Liabilities Fair Value Disclosure
OperatingLeaseLiabilitiesFairValueDisclosure
11003000
CY2020Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
16000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8197261
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29848000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22894000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7782437
CY2020Q2 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
64241094
CY2019Q4 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
61036566
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
103901006
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15697000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12198000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1173458
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
48.18
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
511141
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
247493
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
42.12
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.17
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3745480
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.23
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8197261
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
34.17
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
205800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8210770
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8195866
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005

Files In Submission

Name View Source Status
0001564590-20-033602-index-headers.html Edgar Link pending
0001564590-20-033602-index.html Edgar Link pending
0001564590-20-033602.txt Edgar Link pending
0001564590-20-033602-xbrl.zip Edgar Link pending
crsp-10q_20200630.htm Edgar Link pending
crsp-10q_20200630_htm.xml Edgar Link completed
crsp-20200630.xsd Edgar Link pending
crsp-20200630_cal.xml Edgar Link unprocessable
crsp-20200630_def.xml Edgar Link unprocessable
crsp-20200630_lab.xml Edgar Link unprocessable
crsp-20200630_pre.xml Edgar Link unprocessable
crsp-ex101_293.htm Edgar Link pending
crsp-ex311_8.htm Edgar Link pending
crsp-ex312_6.htm Edgar Link pending
crsp-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending